A bit of perspective

1. The 30 patients in the trial were using ACE inhibitors or ARBs (people who cannot tolerate ACE inhibitors typically use ARBs), which is the current drug treatment.
2. The 2015 global market for ACE inhibitors was about $11 billion USD
3. The market in the US alone for ARBs in 2012/2013 was $8 billion USD

Now, ACE inhibitors and ARBs are prescribed not just for diabetic nephropathy (kidney disease) alone, so the inference we can draw from this study is that the market for "treating" (do these drugs really treat?) diabetic nephropathy, on a global scale has to be upwards of $8-$10 billion USD annually.

Some of the ACE inhibitor drug companies must be taking note of  today's MSB release.....
Like these:
Abbott Laboratories
Pfizer, Inc.
Novartis AG
Merck & Co.
Astra Zeneca plc,
Johnson and Johnson Limited
Eli Lilly and Company
Sanofi SA
Bristol-Myers Squibb Company
Bayer AG
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd., and others.

PS: I will post some revelations about ARBs/ACE inhibitors shortly.